Preeclampsia (PE) is a type of hypertensive disorder of pregnancy characterized by high blood pressure, and proteinuria. PE occurs in 2–8% of pregnancies and potentially contributes to significant fetal, neonatal, and maternal morbidity and mortality.1 The addition of the Siemens Healthineers sFlt-1 and PlGF assays, prognostic markers for preeclampsia, will help to improve the management of this condition.
Robust analytical performance
Broad measuring range
sFlT-1/PIGF (PE) ratio verified based on clinical agreement of results from clinical studies
Clinical performance of PE ratio using a cut-off value of 38
American College of Obstetrics and Gynecology (ACOG) Practice Bulletin No. 222: Obstet Gynecol 2020;135:e237-e260
August et al. UpToDate 2019 Preeclampsia: Clinical features and diagnosis
Lisonkova S, et al. Obstet Gynecol 2014;124:771-81.
World Health Report: Women's and Children's Health. In: WHO, ed. Geneva, Switzerland. 2005
Not available for sale in the US. The products (mentioned herein) are not commercially available in all countries.